Open AccessAnwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth
Author(s) -
Xie Xiaomeng,
Wang Xiangyu,
Shi Xiaodan,
Zhang Yuanyuan,
Laster Kyle Vaughn,
Liu Kangdong,
Dong Zigang,
Kim Dong Joon
Publication year - 2021
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.16289
Subject(s) - in vivo , cancer research , chemistry , lung cancer , cell growth , cell cycle checkpoint , in vitro , kinase , cell , cancer , cell cycle , pharmacology , medicine , biochemistry , biology , oncology , microbiology and biotechnology
Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti‐bacterial, anti‐inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s) against non‐small cell lung cancer (NSCLC) have not been fully elucidated. Anwulignan significantly inhibited cell growth and increased G1‐phase cell cycle arrest in NSCLC cells. Anwulignan strongly attenuates the JAK1/STAT3 signalling pathway by directly targeting JAK1 protein kinase activity in vitro . The anticancer activity by Anwulignan is dependent upon the JAK1 protein expression. Remarkably, Anwulignan strongly inhibited tumour growth in vivo . In conclusion, Anwulignan is a novel JAK1 inhibitor that may have therapeutic implications for NSCLC management.